Sugi Predict

Sugi Predict / Compounds / SCHEMBL4084918

SCHEMBL4084918

SCHEMBL4084918

COc1ccc2cc(-c3n[nH]c4ccc(-c5n[nH]c(C(C)N6CCCC6)n5)cc34)ccc2c1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LRRK2 Q5S007 10/20 0.43
▸ CSNK1D P48730 1/20 0.43
▸ TTK P33981 2/20 0.39
▸ ITK Q08881 4/20 0.39
▸ ABL1 P00519 2/20 0.38
▸ HTR2A P28223 1/20 0.38
▸ HTR2C P28335 1/20 0.38
▸ HTR2B P41595 1/20 0.38
▸ PLK4 O00444 1/20 0.37
▸ CHEK1 O14757 1/20 0.37
▸ AURKA O14965 1/20 0.37
▸ CCNB2 O95067 1/20 0.37
▸ CDK1 P06493 1/20 0.37
▸ PDGFRB P09619 1/20 0.37
▸ CDK4 P11802 1/20 0.37
▸ SRC P12931 1/20 0.37
▸ CCNB1 P14635 1/20 0.37
▸ CCNA2 P20248 1/20 0.37
▸ CCND1 P24385 1/20 0.37
▸ CDK2 P24941 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4084899 0.80 TLR9 (0.42) LRRK2TTKITKABL1HTR2A
SCHEMBL5246773 0.80 CSNK1D (0.68) LRRK2CSNK1DTTKITKABL1
SCHEMBL4090371 0.79 CSNK1D (0.67) LRRK2CSNK1DTTKITKABL1
SCHEMBL4083423 0.78 CSNK1D (0.66) LRRK2CSNK1DTTKITKABL1
SCHEMBL4080023 0.78 CSNK1D (0.56) LRRK2CSNK1DHTR2A
SCHEMBL4084208 0.78 TTK (0.46) LRRK2TTKITKABL1HTR2A
SCHEMBL4084738 0.77 CSNK1D (0.65) LRRK2CSNK1DTTKABL1CHEK1
SCHEMBL4083523 0.77 CSNK1D (0.44) LRRK2CSNK1DTTKITKABL1
SCHEMBL4090728 0.76 TLR9 (0.45) LRRK2TTKITKHTR2AHTR2C
SCHEMBL4080101 0.75 CSNK1D (0.52) LRRK2CSNK1DITKABL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2065383-A1 Indazole compounds and methods of use thereof as protein kinase inhibitors Signal Pharmaceuticals, Inc. (US) 2009-06-03 — — EP disclosed
EP-2065383-A1 Indazole compounds and methods of use thereof as protein kinase inhibitors Signal Pharmaceuticals, Inc. (US) 2009-06-03 — — EP disclosed
US-20090099178-A1 INDAZOLE COMPOUNDS AND METHODS OF USE THEREOF BHAGWAT SHRIPAD S 2009-04-16 — — US disclosed
US-20090099178-A1 INDAZOLE COMPOUNDS AND METHODS OF USE THEREOF BHAGWAT SHRIPAD S 2009-04-16 — — US disclosed
US-20090099178-A1 INDAZOLE COMPOUNDS AND METHODS OF USE THEREOF BHAGWAT SHRIPAD S 2009-04-16 — — US disclosed
EP-1692128-A1 INDAZOLE COMPOUNDS AND METHODS OF USE THEREOF AS PROTEIN KINASE INHIBITORS Signal Pharmaceuticals LLC (US) 2006-08-23 — — EP disclosed
US-20060004043-A1 Indazole compounds and methods of use thereof BHAGWAT SHRIPAD S 2006-01-05 — — US disclosed
WO-2005051942-A1 INDAZOLE COMPOUNDS AND METHODS OF USE THEREOF AS PROTEIN KINASE INHIBITORS SIGNAL PHARMACEUTICALS, LLC (US) 2005-06-09 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090099178-A1 INDAZOLE COMPOUNDS AND METHODS OF USE THEREOF WNT3, WNT3A, WNK3 LRRK2 553/4885CSNK1D 702/4885TTK 401/4885
US-20060004043-A1 Indazole compounds and methods of use thereof WNT3, WNT3A, WNK3 LRRK2 563/4885CSNK1D 687/4885TTK 377/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.